- Home
- QURE vs PTGX Comparison
QURE vs PTGX Comparison
Compare QURE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- PTGX
- Stock Information
- Founded
- QURE 1998
- PTGX 2006
- Country
- QURE Netherlands
- PTGX United States
- Employees
- QURE N/A
- PTGX N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- PTGX Health Care
- Exchange
- QURE Nasdaq
- PTGX Nasdaq
- Market Cap
- QURE 4.3B
- PTGX 5.0B
- IPO Year
- QURE 2007
- PTGX 2016
- Fundamental
- Price
- QURE $30.76
- PTGX $84.73
- Analyst Decision
- QURE Strong Buy
- PTGX Strong Buy
- Analyst Count
- QURE 13
- PTGX 9
- Target Price
- QURE $62.33
- PTGX $86.44
- AVG Volume (30 Days)
- QURE 4.6M
- PTGX 898.8K
- Earning Date
- QURE 11-10-2025
- PTGX 11-06-2025
- Dividend Yield
- QURE N/A
- PTGX N/A
- EPS Growth
- QURE N/A
- PTGX N/A
- EPS
- QURE N/A
- PTGX 0.72
- Revenue
- QURE $15,751,000.00
- PTGX $209,217,000.00
- Revenue This Year
- QURE N/A
- PTGX N/A
- Revenue Next Year
- QURE $229.18
- PTGX $140.23
- P/E Ratio
- QURE N/A
- PTGX $117.70
- Revenue Growth
- QURE N/A
- PTGX N/A
- 52 Week Low
- QURE $5.50
- PTGX $33.31
- 52 Week High
- QURE $71.50
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- QURE 36.57
- PTGX 66.22
- Support Level
- QURE $25.24
- PTGX $82.06
- Resistance Level
- QURE $31.16
- PTGX $86.90
- Average True Range (ATR)
- QURE 3.74
- PTGX 3.10
- MACD
- QURE -2.28
- PTGX 0.25
- Stochastic Oscillator
- QURE 16.43
- PTGX 83.07
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.